ITGB1BP1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10294(ITGB1BP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10294(ITGB1BP1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The ITGB1BP1 antibody targets Integrin Beta-1 Binding Protein 1 (ITGB1BP1), a cytoplasmic protein that interacts with the integrin β1 subunit to regulate cell-matrix adhesion and signaling. ITGB1BP1. also known as MIBP (Mammalian Enabled Interactor) or C9orf147. acts as a modulator of integrin-mediated processes, including cell migration, proliferation, and differentiation. It influences integrin activation states by competing with talin for binding to integrin cytoplasmic tails, thereby fine-tuning cell adhesion dynamics and extracellular matrix interactions.

Antibodies against ITGB1BP1 are essential tools in studying its role in physiological and pathological contexts, such as cancer metastasis, immune responses, and tissue development. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to detect protein expression, localization, and interaction partners. Research has linked ITGB1BP1 dysregulation to tumor progression, where its overexpression or suppression may alter integrin-dependent signaling pathways, impacting cell invasiveness and metastasis.

These antibodies also aid in exploring ITGB1BP1’s involvement in mechanotransduction and its crosstalk with cytoskeletal components. By elucidating ITGB1BP1’s regulatory mechanisms, researchers aim to uncover therapeutic targets for diseases characterized by aberrant cell adhesion, such as fibrosis and cancer.